- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03767582
Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.
January 30, 2024 updated by: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
A Phase I/II Trial of Combination Immunotherapy With Nivolumab and a CCR2/CCR5 Dual Antagonist (BMS-813160) With or Without GVAX Following Chemotherapy and Radiotherapy for Locally Advanced Pancreatic Ductal Adenocarcinomas (PDACs).
The purpose of this study is to evaluate if the combination of nivolumab and a CCR2/CCR5 dual antagonist (BMS-813160) with GVAX is safe in patients with locally advanced pancreatic cancer (LAPC) who have received chemotherapy and radiotherapy, and to see if this combination therapy enhances the infiltration of CD8+CD137+ cells in PDACs .
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
30
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Joann Santmyer
- Phone Number: 410-614-3644
- Email: GIClinicaltrials@jhmi.edu
Study Contact Backup
- Name: Colleen Apostal, RN
- Phone Number: 410-614-3644
- Email: GIClinicalTrials@jhmi.edu
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21231
- Recruiting
- Sidney Kimmel Comprehensive Cancer Center
-
Contact:
- Trish Brothers, RN
- Phone Number: 410-614-3644
- Email: GIClinicaltrials@jhmi.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age ≥18 years.
- Patients with histologically- or cytologically-proven, surgically unresectable, locally advanced pancreatic adenocarcinoma.
- If the patient does not have a diagnostic biopsy that is adequate for review at our institution, the patient must agree to a research core biopsy to be performed at Johns Hopkins.
- If the patient's available imaging is not adequate for review by our institution, the patient must agree to a repeat imaging to be performed at Johns Hopkins.
- Patients cannot have had any prior therapy for the locally advanced pancreatic adenocarcinoma.
- ECOG performance status 0 or 1
- Life expectancy greater than 3 months.
- Able to swallow pills or capsules.
- Patient must have adequate organ function defined by the study-specified laboratory tests.
- Patients must be eligible to receive FOLFIRINOX-based chemotherapy.
- Patients must be willing to be treated with stereotactic body radiation therapy (SBRT) only at Johns Hopkins Hospital.
- Patients must be willing to undergo a core biopsy of the pancreatic cancer.
- Patients must be willing to undergo a biopsy of the pancreatic cancer if the patient is not deemed a surgical candidate during the pre-surgical evaluation.
- Must use acceptable form of birth control while on study.
- Ability to understand and willingness to sign a written informed consent document.
Exclusion Criteria:
- Have had non-FOLFIRINOX-based chemotherapy for the pancreatic cancer.
- Have received any anti-neoplastic biologics, vaccines or hormonal treatment, including investigational drugs, within 28 days of the first dose of study.
- History of past treatment with immunotherapy agents prior to initial enrollment into this study (including, but not limited to: IL-2, interferon, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-OX-40, anti-CD40, anti-CTLA-4 or anti-CCR2/5 drugs).
- Have had prior organ or tissue allograft or allogeneic bone marrow transplantation, including corneal transplants.
- Is currently participating or has participated in a study of an investigational agent or using an investigational device for the treatment of cancer.
- Current use of immunosuppressive medications within 14 days prior to study medications.
- Have received any vaccine within 14 days prior to study medications.
- Receiving growth factors including, but not limited to, granulocyte-colony stimulating factor (G-CSF), GM-CSF, erythropoietin, within 14 days of the first dose of study medication.
- History of any autoimmune disease. Patients with thyroid disease will be allowed.
- Has a history of (non-infectious) pneumonitis or current pneumonitis.
- Has a pulse oximetry < 92% on room air.
- Requires the use of home oxygen.
- Patients with uncontrolled intercurrent illness including, but not limited to, myocardial infarction or stroke/transient ischemic attack within the past 6 months, uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- 12-lead electrocardiogram with QRS ≥ 120 msec, except right bundle branch block ; QTcF (QT corrected for heart rate using Fridericia's method) ≥ 480 msec, except right bundle branch block
- Has an active infection requiring systemic therapy.
- Infection with HIV or hepatitis B or C.
- Any concurrent malignancy other than non-melanoma skin cancer, non-invasive bladder cancer, early stage prostate cancer, or carcinoma in situ of the cervix.
- Current or recent (within 3 months of study treatment administration) gastrointestinal disease that could impact the absorption of study treatment.
- Any gastrointestinal surgery that is likely impact upon the absorption of study treatment.
- Inability to tolerate oral medication.
- Unable to have blood drawn.
- Have had surgery within 28 days of the first dose of study medication.
- Prior use of strong/moderate CYP3A4 inhibitors or inducers within 28 days of the first dose of BMS-813160.
- Prior use of Class I antiarrhythmics within 28 days of first dose of study medication.
- Has ascites requiring medical management.
- Presence of duodenal or gastric invasion by the tumor.
- Hypersensitivity reaction to any monoclonal antibody.
- Known allergy or hypersensitivity to study drugs or any of their components of the study arm that participant is enrolling.
- Woman who are pregnant or breastfeeding.
- Patient is unwilling or unable to follow the study schedule for any reason.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase I - GVAX/Nivolumab/CCR2/CCR5 dual antagonist
|
SBRT (6.6 Gy over 5 days) will be administered between 2 to 4 weeks after chemotherapy.
(Prior to surgery)
Nivolumab (480 mg) will be administered IV over 30 minutes, on day 1 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery).
Post - surgery Nivolumab will be given on Day 1 of cycles 2-5.
Cycles are 4 weeks long.
Other Names:
CCR2/CCR5 dual antagonist (150 mg capsules) will be administered orally twice a day, on days 1-28 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery).
Post - surgery CCR2/CCR5 dual antagonist will be given daily on cycles 2-5.
Cycles are 4 weeks long.
Other Names:
Vaccine (5x10^8 cells) will be administered on day 2 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery).
Post - surgery GVAX will be given on Day 2 of cycles 2-5.
Cycles are 4 weeks long.
Six intradermal injections every 4 weeks.
Other Names:
|
Experimental: Phase II - Arm A: Nivolumab/CCR2/CCR5 dual antagonist
|
SBRT (6.6 Gy over 5 days) will be administered between 2 to 4 weeks after chemotherapy.
(Prior to surgery)
Nivolumab (480 mg) will be administered IV over 30 minutes, on day 1 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery).
Post - surgery Nivolumab will be given on Day 1 of cycles 2-5.
Cycles are 4 weeks long.
Other Names:
CCR2/CCR5 dual antagonist (150 mg capsules) will be administered orally twice a day, on days 1-28 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery).
Post - surgery CCR2/CCR5 dual antagonist will be given daily on cycles 2-5.
Cycles are 4 weeks long.
Other Names:
|
Experimental: Phase II - Arm B: Nivolumab/GVAX/CCR2/CCR5 dual antagonist
|
SBRT (6.6 Gy over 5 days) will be administered between 2 to 4 weeks after chemotherapy.
(Prior to surgery)
Nivolumab (480 mg) will be administered IV over 30 minutes, on day 1 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery).
Post - surgery Nivolumab will be given on Day 1 of cycles 2-5.
Cycles are 4 weeks long.
Other Names:
CCR2/CCR5 dual antagonist (150 mg capsules) will be administered orally twice a day, on days 1-28 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery).
Post - surgery CCR2/CCR5 dual antagonist will be given daily on cycles 2-5.
Cycles are 4 weeks long.
Other Names:
Vaccine (5x10^8 cells) will be administered on day 2 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery).
Post - surgery GVAX will be given on Day 2 of cycles 2-5.
Cycles are 4 weeks long.
Six intradermal injections every 4 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants experiencing study drug-related toxicities
Time Frame: 3 years
|
Number of participants who experienced study drug-related toxicities as defined by CTCAE v5.0
|
3 years
|
Percentage of participants treated with immunotherapy who achieve an immune response
Time Frame: 3 years
|
Percentage of participants who have >80% increase of infiltration of CD8+CD137+ T cells into the pancreatic ductal adenocarcinoma after treatment with immunotherapy compared to baseline before treatment.
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival (OS)
Time Frame: 3 years
|
Number of months from the time of Cycle 1, Day 1 of immunotherapy until death from any cause
|
3 years
|
Metastasis free survival (MFS)
Time Frame: 3 years
|
Number of months from the time of Cycle 1, Day 1 of immunotherapy until first documented distant metastases on imaging per RECIST 1.1 or death from any cause, whichever occurs first.
|
3 years
|
Local progression free survival (LPFS) Time
Time Frame: 3 years
|
Number of months from the time of Cycle 1, Day 1 of immunotherapy until first documented local progression or relapse from complete response on imaging (using RECIST 1.1 criteria and irRECIST criteria) or death from any cause, whichever occurs first.
|
3 years
|
Surgical Resectability Rate
Time Frame: 3 years
|
Number of participants who are able to undergo successful tumor resection (as defined by R0 and R1 resection).
|
3 years
|
Pathological Response Rate
Time Frame: 3 years
|
Number of participants who have a pathologic complete response as determined by surgical margins and residual disease.
|
3 years
|
Change in Quality of life score based on EORTC QLQ-C30/Pan26
Time Frame: Baseline, 3 years
|
Change in quality of life from baseline will be evaluated using the European Organization for Research and Treatment of Cancer core questionnaire, pancreatic cancer module (EORTC QLQ-C30/Pan26).
The QLQ-C30 includes 30 questions assessing global health status/quality of life, function, and symptoms.
The PAN26 module comprises of an additional 26 questions assessing pain, dietary changes, jaundice, altered bowel habit, emotional problems related to pancreatic cancer, and other symptoms (cachexia, indigestion, flatulence, dry mouth, taste changes).
The score for each item ranges from 0-100, with a higher score reflecting a better level of functioning, a better quality of life, or a worse level of symptoms.
|
Baseline, 3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Lei Zheng, MD, Johns Hopkins Medical Institution
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 12, 2019
Primary Completion (Estimated)
December 31, 2024
Study Completion (Estimated)
December 31, 2024
Study Registration Dates
First Submitted
December 5, 2018
First Submitted That Met QC Criteria
December 5, 2018
First Posted (Actual)
December 6, 2018
Study Record Updates
Last Update Posted (Estimated)
January 31, 2024
Last Update Submitted That Met QC Criteria
January 30, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
- Monoclonal antibody
- Nivolumab
- Checkpoint inhibitor
- Immunotherapy
- Anti-PD-1
- Pancreatic Ductal Adenocarcinoma
- SBRT
- Pancreatic cancer
- Neoadjuvant chemotherapy
- Stereotactic body radiation therapy
- Cancer vaccine
- GVAX
- PDAC
- LAPC
- CCR2/CCR5 dual antagonist
- Myeloid modulating agent
- Locally advanced pancreatic ductal adenocarcinoma
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Adenocarcinoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Vaccines
- Nivolumab
Other Study ID Numbers
- J18163
- IRB00190660 (Other Identifier: JHMI IRB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Ductal Adenocarcinoma
-
Roswell Park Cancer InstituteNot yet recruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma and other conditionsUnited States
-
Georgetown UniversityERYtech PharmaActive, not recruitingMetastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
-
Gilead SciencesTerminatedPreviously Untreated Pancreatic Ductal Adenocarcinoma | Relapsed/Refractory Pancreatic Ductal AdenocarcinomaUnited States
-
SOFIERecruitingFAP | PDAC - Pancreatic Ductal AdenocarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Metastatic Pancreatic Cancer | Metastatic Pancreatic Ductal Adenocarcinoma | Primary Pancreatic Ductal AdenocarcinomaUnited States
-
UMC UtrechtDutch Pancreatic Cancer Group (DPCG)Enrolling by invitationResectable Pancreatic Ductal Adenocarcinoma | Recurrent Pancreatic Ductal AdenocarcinomaNetherlands
-
OHSU Knight Cancer InstituteGenentech, Inc.; Oregon Health and Science University; American Association for... and other collaboratorsRecruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal AdenocarcinomaUnited States
-
Sohag UniversityCompletedPancreatic Adenocarcinoma
-
Jonsson Comprehensive Cancer CenterArcus Biosciences, Inc.SuspendedBorderline Resectable Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
Clinical Trials on Stereotactic Body Radiation (SBRT)
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI); NRG OncologyCompletedLung CancerUnited States, Canada
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Active, not recruitingPancreatic Cancer | Periampullary AdenocarcinomaUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Recruiting
-
Sidney Kimmel Comprehensive Cancer Center at Johns...CompletedSarcoma | Metastatic Disease | Bony SitesUnited States
-
New Mexico Cancer Care AllianceCompletedLung Cancer | Non Small Cell Lung Cancer | Solid TumorsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Cancer Prevention Research Institute of TexasActive, not recruitingMetastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Malignant Neoplasms of Urinary Tract | Oligometastatic Renal Cell CarcinomaUnited States
-
Virginia Commonwealth UniversityTerminatedProstate Adenocarcinoma | Stage I Prostate CancerUnited States
-
Centre Hospitalier Universitaire VaudoisActive, not recruitingProstate AdenocarcinomaSwitzerland
-
Centre Leon BerardTerminatedNon-small-cell Lung CarcinomaFrance
-
H. Lee Moffitt Cancer Center and Research InstituteWithdrawn